PharmaCyte Biotech, Inc.
PMCB
$0.72
-$0.03-3.73%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 746.90K | -7.42M | -8.36M | 11.75M | -3.05M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.51M | 6.31M | 7.32M | -14.05M | 2.11M |
| Change in Net Operating Assets | -20.80K | 129.70K | -954.80K | 1.26M | 422.20K |
| Cash from Operations | -786.80K | -979.50K | -1.99M | -1.04M | -509.90K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.00M | -3.00M | -- | 0.00 | 0.00 |
| Cash from Investing | 5.00M | -3.00M | -- | 0.00 | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.05M | -- | -- | -- | -- |
| Repurchase of Common Stock | -401.60K | -- | -- | -171.50K | -225.00K |
| Issuance of Preferred Stock | 0.00 | 6.27M | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | 0.00 | -3.72M |
| Total Dividends Paid | -101.40K | -61.30K | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 543.80K | 6.21M | -- | -171.50K | -3.95M |
| Foreign Exchange rate Adjustments | 2.60K | -400.00 | 100.00 | 600.00 | -1.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.76M | 2.23M | -1.99M | -1.21M | -4.46M |